Latest Research Findings on Next-Generation Antiplatelet Drug SBK019 Published in Circulation Research

On December 5, 2025, the top-tier cardiovascular journal Circulation Research (Volume 137, Number 12) officially published the preclinical research findings of SBK019, a next-generation antiplatelet drug independently developed by Chengdu Shibeikang Biomedical Technology Co., Ltd. (hereinafter referred to as "SBK"). The study, titled “Preclinical Characterization of a Novel and Potent Antiplatelet Drug SBK019”, marks a significant milestone in the field.

The publication of this achievement signifies the international top-tier academic journal's high recognition of SBK's deep commitment to the cardiovascular field, continuous investment in independent innovation, and core technological capabilities.

Circulation Research Published: The Global Benchmark in Cardiovascular Basic Research

As the flagship journal of the American Heart Association (AHA), Circulation Research stands as a global benchmark for cardiovascular basic and translational research. With a 2024 impact factor of 16.5, it consistently ranks among the top 5% of cardiovascular journals worldwide. The journal focuses on groundbreaking achievements with significant originality and high scientific value. Its published content consistently serves as a core reference for global cardiovascular disease research and drug development, establishing its academic authority as an international benchmark in fundamental cardiovascular research.

AHA Late-Breaking Basic Science Recognition: Highlighting Innovation and Translational Value

The AHA Scientific Sessions is one of the largest and most academically prominent international conferences in the cardiovascular field. Its "Late-Breaking Basic Science Abstracts" section employs "groundbreaking" as the core selection criterion, spotlighting the most innovative research achievements with significant scientific value and translational potential.

The AHA Scientific Sessions featured over 4,100 academic abstracts, including more than 700 in Basic Science. Among these, only 55 submissions—including SBK109—were selected as "Late-Breaking Basic Science Abstracts" and published in the latest issue of Circulation Research, representing less than 8% of the total.

Being selected not only signifies international recognition of the researcher's work by the AHA Scientific Sessions but also indicates that the findings will directly influence global cardiovascular disease research directions and clinical practices.

SBK019: AI-Powered Independent R&D, Addressing Metabolic Dependence and Genetic Polymorphism Challenges

SBK019 is a small-molecule antiplatelet drug independently developed by SBK, leveraging the company's proprietary "A-MetaForge™" AI-powered metabolic differentiation research platform. This platform offers a comprehensive technological chain spanning from target discovery to preclinical evaluation. It provided solid technical support and an efficient R&D pathway for the development of SBK019.

Preclinical studies demonstrate that SBK019 exerts its effects by targeting key platelet aggregation pathways, exhibiting potent inhibition, rapid onset, and a wide safety window. It effectively overcomes CYP450 enzyme metabolic dependency, ensuring stable efficacy across populations with genetic polymorphisms. It delivers an innovative solution for antiplatelet therapy that is potent, safe, and suitable for a broad patient population.

《Circulation Research》（Volume 137, Number 12）：Late-Breaking Basic Science Abstracts From the American Heart Association’s Scientific Sessions 2025 | Circulation Research